Ilana Usiskin, Mary Jeffway, Ying Qi, Nancy Shadick, Michael Weinblatt, Brittany Weber, Katherine Liao
{"title":"Characteristics Associated With Detectable High-Sensitivity Cardiac Troponin in Patients With Rheumatoid Arthritis at Low-Intermediate Cardiac Risk.","authors":"Ilana Usiskin, Mary Jeffway, Ying Qi, Nancy Shadick, Michael Weinblatt, Brittany Weber, Katherine Liao","doi":"10.1002/acr2.70063","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to identify factors associated with detectable high-sensitivity cardiac troponin T (hs-cTnT), a marker of subclinical myocardial injury associated with cardiac events in rheumatoid arthritis (RA), among patients with RA at low to intermediate atherosclerotic cardiovascular disease (ASCVD) risk.</p><p><strong>Methods: </strong>We performed a cross-sectional cohort study among patients with RA, excluding those with pre-existing cardiovascular disease or high estimated 10-year ASCVD risk (>20%). In univariable analysis, we compared demographics, RA clinical factors, markers of inflammation, and routine lipids among patients with and without detectable hs-cTnT. Multivariable logistic regression models were constructed to determine whether clinical factors and clinically available biomarkers were associated with detectable hs-cTnT, independent of ASCVD risk.</p><p><strong>Results: </strong>We studied 294 patients with RA, of whom 86 (29%) had a detectable hs-cTnT level. Older age; male sex; hypertension; higher levels of high-sensitivity C-reactive protein, interleukin-6, and lipoprotein-associated phospholipase A<sub>2</sub>; glucocorticoid use; and the absence of methotrexate use were associated with detectable hs-cTnT. Higher 10-year ASCVD risk was associated with detectable hs-cTnT (odds ratio 1.22, 95% confidence interval 1.15-1.29); markers of inflammation were not associated with detectable hs-cTnT in multivariable analysis. Among patients with RA in the lowest ASCVD risk category (10-year risk <5%), more than 25% of men and more than 33% of patients aged >60 had detectable hs-cTnT.</p><p><strong>Conclusion: </strong>Detectable hs-cTnT was prevalent among a cohort of patients with RA with low to intermediate ASCVD risk. Patients who were male or aged >60 had the highest rates of detectable hs-cTnT, suggesting a role for additional screening in these individuals regardless of their ASCVD risk.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"7 8","pages":"e70063"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317461/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACR open rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/acr2.70063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The objective of this study was to identify factors associated with detectable high-sensitivity cardiac troponin T (hs-cTnT), a marker of subclinical myocardial injury associated with cardiac events in rheumatoid arthritis (RA), among patients with RA at low to intermediate atherosclerotic cardiovascular disease (ASCVD) risk.
Methods: We performed a cross-sectional cohort study among patients with RA, excluding those with pre-existing cardiovascular disease or high estimated 10-year ASCVD risk (>20%). In univariable analysis, we compared demographics, RA clinical factors, markers of inflammation, and routine lipids among patients with and without detectable hs-cTnT. Multivariable logistic regression models were constructed to determine whether clinical factors and clinically available biomarkers were associated with detectable hs-cTnT, independent of ASCVD risk.
Results: We studied 294 patients with RA, of whom 86 (29%) had a detectable hs-cTnT level. Older age; male sex; hypertension; higher levels of high-sensitivity C-reactive protein, interleukin-6, and lipoprotein-associated phospholipase A2; glucocorticoid use; and the absence of methotrexate use were associated with detectable hs-cTnT. Higher 10-year ASCVD risk was associated with detectable hs-cTnT (odds ratio 1.22, 95% confidence interval 1.15-1.29); markers of inflammation were not associated with detectable hs-cTnT in multivariable analysis. Among patients with RA in the lowest ASCVD risk category (10-year risk <5%), more than 25% of men and more than 33% of patients aged >60 had detectable hs-cTnT.
Conclusion: Detectable hs-cTnT was prevalent among a cohort of patients with RA with low to intermediate ASCVD risk. Patients who were male or aged >60 had the highest rates of detectable hs-cTnT, suggesting a role for additional screening in these individuals regardless of their ASCVD risk.